SCHEMBL472469

SCHEMBL472469

Cc1nc(Cl)oc1-c1ccc(C(F)(F)F)c(F)c1F

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.34
TRPV4 Q9HBA0 2/20 0.34
MPL P40238 2/20 0.33
TRPV1 Q8NER1 1/20 0.32
TRPV3 Q8NET8 1/20 0.32
NOTUM Q6P988 1/20 0.31
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
HSD11B1 P28845 4/20 0.31
KLKB1 P03952 1/20 0.31
KDM4E B2RXH2 1/20 0.30
CXCR4 P61073 1/20 0.30
GRM8 O00222 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C9 P11712 1/20 0.30
TACR1 P25103 1/20 0.30
GRM7 Q14831 1/20 0.30
PDE2A O00408 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL472359 0.78 PDE2A (0.38) MPLTRPV3NOTUMHSD11B1CYP2C9
SCHEMBL472351 0.75 CYP11B2 (0.48)
SCHEMBL472356 0.75 HSD11B1 (0.46) MPLNOTUMHSD11B1PDE2A
SCHEMBL472456 0.73 GRM2 (0.41) TRPV3NOTUMCYP1A2PDE2A
SCHEMBL472420 0.73 IMPDH2 (0.34) MPLNOTUMPDE2A
SCHEMBL9954602 0.70 NPC1 (0.41) MPLHSD11B1KDM4EPDE2A
SCHEMBL472556 0.69 MAPT (0.41) TRPV1NOTUM
SCHEMBL472478 0.69 NMUR2 (0.40) CYP1A2CYP2C9PDE2A
SCHEMBL472390 0.68 UTRN (0.32)
SCHEMBL472399 0.67 NOTUM (0.45) NOTUMHSD11B1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2412372-A1 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases Abbott Laboratories (US) 2012-02-01 EP disclosed
US-7998993-B2 TRPV1 antagonists ABBOTT LABORATORIES (US) 2011-08-16 US disclosed
EP-2220059-B1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LAB (US) 2011-08-03 EP disclosed
EP-2220059-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN Abbott Laboratories (US) 2010-08-25 EP disclosed
US-20090124666-A1 TRPV1 ANTAGONISTS ABBOTT LABORATORIES (US) 2009-05-14 US disclosed
WO-2009055749-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LABORATORIES (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124666-A1 TRPV1 ANTAGONISTS TRPV1, TRPV2, TRPV3 TRPA1 5/4885TRPV4 4/4885MPL 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.